I
Intellia Therapeutics, Inc. (NTLA)
NGM – Real Time Price. Currency in USD
16.68
+0.65 (4.05%)
At close: Jun 26, 2026, 4:00 PM EDT
16.61
-0.07 (-0.42%)
After-hours: Jun 26, 2026, 7:58 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
16.68
+0.65 (4.05%)
At close: Jun 26, 2026, 4:00 PM EDT
16.61
-0.07 (-0.42%)
After-hours: Jun 26, 2026, 7:58 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $134.7M significantly exceed its total debt $80.5M, ensuring strong financial flexibility
Total current assets $466.4M exceed Total current liabilities $76.4M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$117.4M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 6.10 | 6.05 | 10 | |
| Quick ratio | 6.10 | 5.63 | 10 | |
| Debt to Equity | 0.13 | 0.30 | 9.0 | |
| Debt to Assets | 0.11 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 52M | 36M | 58M | 68M | 66M |
| Gross Profit | 45M | 27M | 48M | 52M | 50M |
| Operating Income | -458M | -515M | -534M | -441M | -421M |
| Net Income | -474M | -481M | -519M | -413M | -395M |
| EBITDA | -451M | -506M | -524M | -425M | -405M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -7.45 | 17.58 | 5.0 |
| Next quarter | -3.95 | 13 | 4.5 |
| Current year | -12.77 | 15.48 | 5.0 |
| Next year | 355.53 | 42.56 | 10 |
| Weighted average score | 6.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -34.61 | -0.45 | 2.41 | -69.16 | 1.5 |
| Y/Y | -9.49 | 15.83 | 26.36 | 21.54 | 7.5 |
| 3y average | 15.36 | 3.72 | 14.19 | -5.38 | 5.5 |
| 5y average | 12.15 | -33.07 | -15.56 | -81.29 | 2.5 |
| Weighted average score | 4.3 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |